Physician profile
Jill M Larkin
NPI 1942294830
$554.28
in general payments reported to CMS, 2019-2025
15 companies · $97.46 in 2025
The $97.46 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.23 · 2020: $82.84 · 2021: $128 · 2022: $58.66 · 2023: $137 · 2024: $25.73 · 2025: $97.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $93.35 | 2020-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $86.71 | 2020-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $73.38 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $46.66 | 2022-2023 | |
| Abbvie INC. | $36.48 | 2023 | |
| Amgen INC. | $31.44 | 2019-2025 | Evenity |
| Teva Pharmaceuticals USA, INC. | $29.72 | 2022 | |
| Ibsa Pharma INC. | $26.67 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $24.27 | 2021 | |
| Allergan, INC. | $23.70 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.96 | 2023 | Trintellix |
| Halozyme INC | $15.83 | 2023 | |
| Endogastric Solutions, INC | $12.50 | 2023 | Esophyx |
| Bardy Diagnostics, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.